Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal
Following recent licensing pacts with Pfizer and CSPC, Madrigal will add six preclinical siRNA candidates to its MASH portfolio via an agreement with China’s Ribo Life Science.
Scrip - February 11, 2026

Upstream To Upgrade Verekitug To Phase III After Positive Asthma Results
The company announced topline results from its Phase II VALIANT trial, which follow chronic rhinosinusitis data that it announced in September.
Scrip - February 11, 2026

AstraZeneca And Daiichi-Sankyo Stack The Odds For Datroway’s Lung Cancer Bets
The partners are targeting non-squamous patients and using AstraZeneca’s proprietary tumor profiling technology to boost Datroway’s chances of success in its upcoming pivotal trials.
Scrip - February 11, 2026

Drug Makers Confront Headwinds In 2026, But MFN Doesn’t Seem Like A Big One
Exclusivity losses and US drug pricing pressure are challenges large-cap pharma companies will need to navigate, with many forecasting modest growth in 2026.
Scrip - February 11, 2026

Drug Makers Confront Headwinds In 2026, But MFN Doesn’t Seem Like A Big One
Exclusivity losses and US drug pricing pressure are challenges large-cap pharma companies will need to navigate, with many forecasting modest growth in 2026.
Scrip - February 11, 2026

Nektar Shares Surge On Phase IIb Rezpeg Atopic Dermatitis Data
Following 52-week maintenance data showing sustained and deepening responses, Nektar plans to advance rezpegaldesleukin into Phase III development, targeting a 2029 BLA submission.
Scrip - February 11, 2026

Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation
Incyte’s pricing moves to broaden Opzelura’s formulary access are expected to weigh on revenue in 2026, leaving the drug’s sales outlook slightly below consensus.
Scrip - February 11, 2026

Scrip Asks... What Does 2026 Hold For Biopharma? Part 5: AI And Operational Excellence
About 50 pharmaceutical industry leaders surveyed by Scrip predict 2026 will mark AI's shift from pilot programs to committed operational deployment. However, competitive advantage will depend on organizational transformation and digital infrastructure maturity, not algorithmic sophistication alone.
Scrip - February 11, 2026

India Pharma Chiefs On Driving Innovation, China’s Rise And Past Patent Tussles
Indian industry stalwarts discuss taking a leaf out of China’s book to lead in biopharma innovation, call for “greater acceptability” of indigenously developed therapies and reflect on the historical struggle for changes in India's patent laws, including an incident that jolted a prime minister.
Scrip - February 11, 2026

FDA Tosses Flu Vaccine Application Back To Moderna With RTF Letter
Moderna said the refusal-to-file (RTF) letter the US FDA issued declining to review the BLA for mRNA-1010 was not in line with guidance from the agency before and after the seasonal influenza vaccine candidate’s Phase III program.
Scrip - February 11, 2026

Solace Health Raises $130M In Series C Round Bringing It To $1Bn Valuation
Health tech start-up Solace Health raised $130m in a series C funding round, which will allow it to expand its national network of more than 2,000 advocates serving Medicare and Medicare Advantage members.
Medtech Insight - February 11, 2026

Bringing Net Zero Onto The Radar For UK Healthtech Innovators
A program to help healthtech innovators comply with NHS sustainability targets without compromising their unique R&D propositions has been launched by the UK government’s healthcare research arm and the Pd-m consultancy.
Medtech Insight - February 11, 2026

Estée Lauder Sues Walmart Alleging Sale of Counterfeit Beauty Products
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026

CVS To Prefer Denosumab Biosimilars, Drop Prolia From Key US Formularies
Samsung Bioepis’ Ospomyv and Celltrion’s Stoboclo will be preferred on major US commercial formularies from April 2026, as CVS Caremark drops Prolia and another higher-cost brand, Forteo (teriparatide), to drive savings.
Generics Bulletin - February 11, 2026

Formycon Strikes A Keytruda Biosimilar Deal With Lotus For APAC Markets
Formycon bagged a third commercialization opportunity for its pembrolizumab candidate FYB206, with Lotus Pharmaceutical taking over rights for the APAC region.
Generics Bulletin - February 11, 2026

Intas And Kashiv Ally On Complex Peptide
Kashiv Biosciences and Intas Pharmaceuticals have announced a licensing and supply collaboration on an undisclosed complex peptide for the European, UK and Indian markets.
Generics Bulletin - February 11, 2026

Celltrion Outlines Plan To Quadruple Biosimilar Portfolio By 2038
The Korean player plans to expand its biosimilar portfolio to more than 40 products by 2038, while advancing late-stage candidates including a streamlined Phase III trial of its secukinumab biosimilar.
Generics Bulletin - February 11, 2026

Immunis Bets Longevity Medicine Needs a Business Model, Not Just Biology
Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.
In Vivo - February 11, 2026